Researchers have discovered a molecular pathway in colorectal cancer cells that leads to uncontrolled division, creating an avenue for more targeted therapies.
Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.
A new microfluidic liver-on-a-chip platform offers drug developers a stable, scalable and sensitive testing ground for much-needed treatments in fatty liver disease.